Dr. Tripathy Discusses Biomarker Use in Clinical Trials

Video

Dr. Debu Tripathy from the USC Norris Comprehensive Cancer Center Discusses Biomarker Use in Clinical Trials

Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, explains that clinical trials have adapted the use of biomarkers into the design of each study.

Trials are beginning to be designed not only to look at how a biomarker influences response but also its effect on overall survival and progression-free survival. Trials will be looking for biomarkers that not only predict a response but also show an improvement in survival.

Tripathy explains it is becoming uncommon to see a trial that is not containing a biomarker investigation.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD